Intelligent Bio Solutions (INBS) Stock: Buy, Sell, or Hold?
INBS - Intelligent Bio Solutions Inc. Common Stock
$1.66
0.00 (0.00%)
▲
5d:
-2.35%
30d:
-32.79%
90d:
-27.19%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When INBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INBS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: INBS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: INBS is currently trading at $1.66, which is considered oversold relative to its 30-day fair value range of $1.76 to $2.31. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.3) compared to its historical average (13.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INBS is in a downtrend. Immediate support is located at $1.60, while resistance sits at $1.96.
Market Sentiment: INBS scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+622.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INBS is in a downtrend. Immediate support is located at $1.60, while resistance sits at $1.96.
Market Sentiment: INBS scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+622.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.76 -
$2.31
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 622.9% below Wall St target ($12.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 42% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.76 -
$2.31
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$1.96
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.32
Wall Street Target
$12.00
(+622.9%)
Revenue Growth (YoY)
35.8%
Profit Margin
-294.9%
PE vs Historical
-0.3 vs 13.0
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 9:06 PM ET
Data refreshes hourly during market hours. Next update: 10:06 PM
Data refreshes hourly during market hours. Next update: 10:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 64 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 51 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 58 HOLD |